Fig. 5: Potential clinical use case of the Orpheus recurrence risk prediction model.
From: Multimodal histopathologic models stratify hormone receptor-positive early breast cancer
The Orpheus multimodal prediction model for recurrence risk prediction is potentially capable of guiding decision-making for adjuvant cytotoxic chemotherapy alongside adjuvant endocrine therapy for predicted low- and high-risk patients. The model is within scope for early-stage hormone receptor-positive (HR+) and HER2- breast cancer patients. Created in BioRender. Marra, A. (2025) https://BioRender.com/l96q019.
